TY - JOUR T1 - The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses JF - medRxiv DO - 10.1101/2021.05.03.21256520 SP - 2021.05.03.21256520 AU - Konstantin Föhse AU - Büsra Geckin AU - Martijn Zoodsma AU - Gizem Kilic AU - Zhaoli Liu AU - Rutger J. Röring AU - Gijs J. Overheul AU - Josephine S. van de Maat AU - Ozlem Bulut AU - Jacobien J. Hoogerwerf AU - Jaap ten Oever AU - Elles Simonetti AU - Heiner Schaal AU - Ortwin Adams AU - Lisa Müller AU - Philipp Niklas Ostermann AU - Frank L. van de Veerdonk AU - Leo A.B. Joosten AU - Bart L. Haagmans AU - Reinout van Crevel AU - Ronald P. van Rij AU - Corine GeurtsvanKessel AU - Marien I. de Jonge AU - Yang Li AU - Jorge Domínguez-Andrés AU - Mihai G. Netea Y1 - 2023/01/01 UR - http://medrxiv.org/content/early/2023/03/27/2021.05.03.21256520.abstract N2 - The mRNA-based BNT162b2 protects against severe disease and mortality caused by SARS-CoV-2 through induction of specific antibody and T-cell responses. Much less is known about its broad effects on immune responses against other pathogens. In the present study, we investigated the specific adaptive immune responses induced by BNT162b2 vaccination against various SARS-CoV-2 variants, as well as its effects on the responsiveness of human immune cells upon stimulation with heterologous viral, bacterial, and fungal pathogens. BNT162b2 vaccination induced effective humoral and cellular immunity against SARS-CoV-2 that started to wane after six months. We also observed long-term transcriptional changes in immune cells after vaccination, as assessed by RNA sequencing. Additionally, vaccination with BNT162b2 modulated innate immune responses as measured by the production of inflammatory cytokines when stimulated with various microbial stimuli other than SARS-CoV-2, including higher IL-1/IL-6 release and decreased production of IFN-α. Altogether, these data expand our knowledge regarding the overall immunological effects of this new class of vaccines and underline the need of additional studies to elucidate their effects on both innate and adaptive immune responses.Competing Interest StatementM.G.N and L.A.B.J are scientific founders of TTxD and Lemba.Clinical TrialEudraCT 2021-000182-33Funding StatementL.A.B.J. is supported by a Competitiveness Operational Program Grant of the Romanian Ministry of European Funds (HINT, ID P_37_762; MySMIS 103587). J.D-A. is supported by the Netherlands Organization for Scientific Research (VENI grant 09150161910024 and Off-Road grant 04510012010022). M.G.N. is supported by an ERC Advanced Grant (#833247) and a Spinoza Grant of the Netherlands Organization for Scientific Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Arnhem-Nijmegen Institutional Review BoardI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data is available upon request. ER -